--- title: "The first certificate for invasive brain-machine interfaces has been issued, and medical innovation ETFs are attracting attention" type: "News" locale: "en" url: "https://longbridge.com/en/news/279194307.md" description: "The first invasive brain-computer interface has been approved, with Borui Kang Medical's implanted brain-computer interface receiving NMPA approval for market launch, marking the entry of the domestic brain-computer interface industry into the clinical application stage. The latest quote for the Medical Innovation ETF (516820) is 0.36 yuan, with an average daily transaction of 51.36 million yuan over the past year, reaching a scale of 1.842 billion yuan. The constituents of the CSI Medicine and Medical Device Innovation Index (931484) show mixed performance, and Century Securities recommends paying attention to medical device companies with invasive brain-computer interface technology" datetime: "2026-03-16T02:44:12.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/279194307.md) - [en](https://longbridge.com/en/news/279194307.md) - [zh-HK](https://longbridge.com/zh-HK/news/279194307.md) --- # The first certificate for invasive brain-machine interfaces has been issued, and medical innovation ETFs are attracting attention As of March 16, 2026, 10:01, the components of the CSI Medicine and Medical Device Innovation Index (931484) showed mixed performance, with Pian Zai Huang leading with a 2.39% increase, Shenzhou Cell rising by 2.01%, and Huatai Medical up by 1.38%; Yingke Medical led the decline. The latest quote for the Medical Innovation ETF (516820) is 0.36 yuan. In terms of liquidity, the Medical Innovation ETF had a turnover of 0.38% during the session, with a transaction volume of 7.0469 million yuan. Looking at a longer time frame, as of March 13, the average daily transaction volume of the Medical Innovation ETF over the past year was 51.3617 million yuan. In terms of scale, the latest size of the Medical Innovation ETF reached 1.842 billion yuan. (Data source: Wind) On the news front, the first invasive brain-machine interface has been approved. On March 13, Boleikang Medical's implanted brain-machine interface hand movement compensation system received NMPA approval for market launch, entering clinical application as the world's first invasive brain-machine interface medical device. This product uses minimally invasive epidural implantation and wireless power communication technology, suitable for patients with quadriplegia caused by C2-C6 cervical spinal cord injuries. This milestone event marks the synchronization of top-level design and regulatory practice in the domestic brain-machine interface industry, transitioning from early conceptual research and development to later clinical applications. Century Securities believes that as a future industry intersecting multiple disciplines, brain-machine interfaces have a first-mover execution advantage in domestic clinical advancement. Approved devices will gradually enter hospitals to accumulate real-world data, and the underlying software and hardware platforms that have verified safety are expected to continue iterating and optimizing to expand indications. It is recommended to pay attention to specialized medical service providers that possess core neurosurgery clinical resources and data access, as well as innovative medical device companies with invasive brain-machine interface technology platforms. The Medical Innovation ETF closely tracks the CSI Medicine and Medical Device Innovation Index, which selects 30 publicly listed companies with good profitability, certain growth potential, and research and innovation capabilities from the pharmaceutical and healthcare industry as index samples, reflecting the overall performance of publicly listed pharmaceutical and medical device companies that combine profitability and growth. Data shows that as of February 27, 2026, the top ten weighted stocks in the CSI Medicine and Medical Device Innovation Index (931484) are WuXi AppTec, Mindray Medical, Heng Rui Medicine, Aier Eye Hospital, Pian Zai Huang, New Hope Liuhe, East China Pharmaceutical, Kanglong Huacheng, Ailisi, and Dong'e Ejiao, with the top ten weighted stocks accounting for a total of 63.75%. Risk Warning: Funds carry risks, and investment requires caution. The fund manager promises to manage and utilize fund assets based on the principles of honesty, credit, diligence, and responsibility, but does not guarantee that this fund will definitely make a profit, nor does it guarantee a minimum return. The fund manager reminds investors of the "buyer bears the risk" principle in fund investment; after making an investment decision, the investment risks arising from the fund's operational status and changes in net asset value are borne by the investors themselves. The past performance of the fund and its net asset value does not indicate its future performance, and the performance of other funds managed by the fund manager does not constitute a guarantee of this fund's performance. Investors purchasing funds may share in the income generated by the fund's investments according to their held shares, but they may also bear the losses brought about by the fund's investments Investors should carefully read the "Fund Contract," "Prospectus," and other legal documents of the fund, fully understand the risk-return characteristics and product features of this fund, and assess whether the fund aligns with their risk tolerance based on their investment objectives, investment horizon, investment experience, and asset status. They should make rational market judgments and exercise caution in making investment decisions. The relevant information in this material is sourced from publicly available materials deemed reliable by the fund manager, and the related opinions, assessments, and forecasts reflect current judgments that may change in the future. Any market opinions contained in this material are based on corresponding assumptions, and any assumptions may change at any time. The fund manager does not promise or guarantee that any predictive market opinions will necessarily be realized. The individual stocks mentioned in the material do not constitute investment recommendations or advice. The fluctuations in the secondary market of ETF funds do not represent the actual return rate of the fund; investors should pay attention to the risks of price volatility in the market ### Related Stocks - [516820.CN](https://longbridge.com/en/quote/516820.CN.md) - [560600.CN](https://longbridge.com/en/quote/560600.CN.md) - [160635.CN](https://longbridge.com/en/quote/160635.CN.md) - [003008.CN](https://longbridge.com/en/quote/003008.CN.md) - [159898.CN](https://longbridge.com/en/quote/159898.CN.md) ## Related News & Research - [Broncus shareholders back all AGM resolutions, update articles of association](https://longbridge.com/en/news/286439966.md) - [Manulife Singapore to offer multi-cancer blood test starting May](https://longbridge.com/en/news/286710691.md) - [05:54 ETTermHub™ Launches New Managed FHIR Offering for SDOs](https://longbridge.com/en/news/287042225.md) - [Trump faces record-low approval on inflation as retirees struggle](https://longbridge.com/en/news/286834439.md) - [Hong Kong’s MPF authority flags fraudulent certificates in early pension payouts](https://longbridge.com/en/news/286657515.md)